GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more
Location: 1525 O’Brien Drive, Menlo Park, CA, 94025, United States | Website: https://grail.com | Industry: Diagnostics & Research | Sector: Healthcare
Market Cap
3.243B
52 Wk Range
$13.58 - $103.00
Previous Close
$83.20
Open
$77.68
Volume
1,166,143
Day Range
$75.00 - $84.80
Enterprise Value
2.623B
Cash
540.1M
Avg Qtr Burn
-82.18M
Insider Ownership
12.94%
Institutional Own.
64.78%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
